Key Takeaway: Nurix has disclosed NX-5948, an oral targeted degrader of Bruton’s Tyrosine Kinase (BTK), aimed at treating B-cell malignancies. This development is part of Nurix's broader strategy to advance innovative therapies for cancer and autoimmune diseases. The company emphasizes its commitment to translating scientific insights into effective treatments.
Price reaction · baseline $8.86 (2023-08-16T14:27:00.000Z) · hit during market hours · clean, no other NRIX news in the window
day 0 close · peak
-2.9%
Market Sentiment Analysis
POSITIVE FACTORS
Introduction of NX-5948 as a novel treatment option.
Focus on targeted degradation of BTK for B-cell malignancies.
Commitment to advancing therapies for cancer and autoimmune diseases.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+85%
120-day peak, hindsight
Typical move
4.4%
average across 9 past catalysts
Cash runway
~14 mo
Low dilution risk
Lead asset
NX-5948
Phase 3 · B-cell Lymphoma
Full Press Release Details
RESOURCE LIBRARY
RESOURCE LIBRARY
At Nurix, we are dedicated to translating novel scientific insights into breakthrough therapies, advancing our multi-modal portfolio of wholly owned and partnered assets to outmatch cancer and autoimmune disease. Access our protein degradation resources below.
Filter by
Frequently Asked Questions
What is NX-5948?
NX-5948 is an oral targeted degrader of Bruton's Tyrosine Kinase (BTK).
What conditions does NX-5948 aim to treat?
NX-5948 is designed for the treatment of B-cell malignancies.
What is the significance of BTK in cancer treatment?
BTK plays a crucial role in B-cell signaling, making it a target for cancer therapies.
Who is developing NX-5948?
NX-5948 is being developed by Nurix, a biopharmaceutical company.